title: [Unidentified Inflammatory Disease Induced by Azacitidine Therapy for Myelodysplastic Syndrome].
abstract: We report a 73-year-old woman with myelodysplastic syndromes (MDS) of the refractory anemia with excess of blasts-1 subtype, which was diagnosed in April 2014 on the basis of cytopenia for two cell types. After completing 3cycles of azacitidine (AZA) therapy, the patient was admitted to our hospital based on an initial presentation of high fever. During hospitalization, the high fever and increasing inflammatory reaction persisted. We reevaluated the effect of MDS in this patient and concluded that the AZA administration was successful and the MDS was extremely stable. On medical examination and inspection, the patient had an unidentified inflammatory disease. First, we treated her with high-dose steroid pulse therapy. However, the effect of the treatment was transient. Furthermore, the effects of cyclosporin A and oral steroid therapy were poor; therefore, we initiated tocilizumab administration. Nevertheless, she died of multiorgan failure. An increasing serum IL- 6 level induced by the AZA therapy was later confirmed. Recent studies have reported the immunomodulatory effects stimulated by AZA therapy in MDS. This case is a valuable reminder that an unidentified inflammatory disease can be induced in the course of AZA therapy for MDS.
authors.affiliation: Division of Hematology, Shonan Kamakura General Hospital.
authors.forename: Shunichiro
authors.initials: S
authors.lastname: Inagaki
authors.forename: Yotaro
authors.initials: Y
authors.lastname: Tamai
authors.forename: Masaki
authors.initials: M
authors.lastname: Yoshizawa
authors.forename: Shuku
authors.initials: S
authors.lastname: Sato
authors.forename: Emiko
authors.initials: E
authors.lastname: Kanbe
authors.forename: Eri
authors.initials: E
authors.lastname: Tanaka
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000150:complications; D015850:Interleukin-6 / Q000097:blood; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy*
chemical_list: C508600:IL6 protein, human; D015850:Interleukin-6; D001374:Azacitidine